전임상 CRO 시장 규모, 점유율, 동향 분석 보고서 : 서비스별, 개발 단계별, 적응증별, 모델별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Preclinical CRO Market Summary

The global preclinical CRO market size was estimated at USD 6.7 billion in 2025 and is projected to reach USD 12.8 billion by 2033, growing at a CAGR of 8.4% from 2026 to 2033. The market growth is driven by economic outsourcing, regulatory mandates, and scientific complexities, which, in turn, make preclinical CROs a critical component of the early-stage drug development process.

Besides, the rising demand for toxicology, pharmacology, and efficacy studies is expected to drive market growth. The outsourcing trends of preclinical research, particularly among biotech and biopharma companies seeking to minimize fixed infrastructure costs, shorten development timelines, and access specialized expertise, are expected to significantly contribute to future growth. Moreover, increasing complexity in drug development, higher biopharma R&D investments, and stringent regulations requiring Good Laboratory Practice (GLP)-compliant studies are influencing the market growth. Thus, these factors are driving manufacturers to rely more on CROs to optimize costs and reduce operational burdens, thereby fueling market growth.

The market is anticipated to grow owing to growing R&D offshoring and the rising outsourcing trend, increasing demand for personalized medicine and advanced therapeutics, increasing pharmaceutical R&D investments, and the integration of translational biomarkers into preclinical studies, among others.

The trend of R&D offshoring is attributed to structural shifts in the pharmaceutical and biotechnology industries. Since the R&D costs for developing new drugs are high, coupled with longer discovery timelines and increasing complexity, the manufacturers are relying on outsourcing to CROs at cost-effective locations for conducting preclinical studies. This R&D offshoring allows companies to leverage the availability of highly skilled resources, advanced infrastructure, and laboratory capacity at significantly lower cost than in the U.S. and Europe, especially for smaller and mid-sized biopharma companies without internal capabilities, and for large pharma to improve capital efficiency.

The developing markets, including India and China, have emerged as major centers with GLP-compliant facilities, integrated service offerings, and cost advantages of 30-60% over other locations. The CROs in these countries offer comprehensive capabilities, including discovery, toxicology, DMPK, and in vivo studies, enabling faster, more flexible studies. Moreover, the development of hybrid R&D operations, including both onshore strategy and offshore execution, has further strengthened this trend.

In addition, strategic collaborations and initiatives undertaken by the companies are further bolstering the outsourcing growth. For instance, in February 2026, Syngene International signed a partnership agreement with Johns Hopkins University, leveraging discovery and preclinical capabilities to advance early-stage research into clinical candidates. Similarly, in January 2026, Syngene International extended its existing collaboration with Bristol Myers Squibb through 2035, providing a dedicated R&D extension including discovery, preclinical, and manufacturing capabilities. Such initiatives are likely to propel the market growth over the forecast period.

Furthermore, the demand for personalized medicine and advanced therapeutics is driving the growth of preclinical CROs, driven by factors such as the rising need for new drug discoveries to combat the increasing incidence of chronic illnesses worldwide, as well as companies' strategic initiatives and technology integration. For instance, in March 2026, NJ Bio and Ajinomoto Bio-Pharma Services partnered to enhance NJ Bio's capabilities in antibody-drug conjugate development by integrating the AJICAP technology into its workflow. This will allow modification of the antibody at a site-specific level, thereby improving the stability, efficacy, and pharmacokinetics of the antibody-drug conjugate.

Similarly, in March 2026, Eli Lilly and Insilico Medicine partnered by signing an agreement valued at up to USD 2.75 billion to enhance drug discovery using artificial intelligence technology. The partnership agreement grants Eli Lilly exclusive global rights to the development and commercialization of selected oral drug candidates currently in preclinical development. In return, Insilico Medicine will receive royalty payments and leverage its AI technology to discover new disease targets and speed up its pipeline. Thus, an increase in the demand for advanced therapeutics and personalized medicines is likely to impel the market's growth over the coming years.

Global Preclinical CRO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global preclinical CRO market report based on service, development stage, indication, model, end use, and region.

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Bioanalysis and DMPK studies
  • In vitro ADME
  • In-vivo PK
• Toxicology Testing
  • GLP
  • Non-GLP
• Compound Management
  • Process R&D
  • Custom Synthesis
  • Others
• Chemistry
  • Medicinal Chemistry
  • Computation Chemistry
• Safety Pharmacology
• Others
• Development Stage Outlook (Revenue, USD Million, 2021 - 2033)
• Target Discovery
• Preclinical Optimization, Efficacy & PK/PD
• IND-Enabling Safety (GLP)
• Bioanalysis & Analytics
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• CNS
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Disorders
• Rare Diseases
• Others
• Model Outlook (Revenue, USD Million, 2021 - 2033)
• In Vitro
• In Vivo
• Ex Vivo
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical and Biopharmaceutical Companies
• Medical Device Companies
• Academic and Research Institutes
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Development Stage
  • 1.2.3. Indication
  • 1.2.4. Model
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Preclinical CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing R&D Offshoring and Rising Outsourcing Trend
    • 3.2.1.2. Increasing Demand for Personalized Medicine and Advanced Therapeutics
    • 3.2.1.3. Rising Pharmaceutical R&D Investments
    • 3.2.1.4. Integration of Translational Biomarkers into Preclinical Studies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Monitoring Issues and Lack of Standardization
    • 3.2.2.2. Managing Relationships
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Preclinical CRO Market: Service Estimates & Trend Analysis

• 4.1. Preclinical CRO Market, By Service: Segment Dashboard
• 4.2. Preclinical CRO Market, By Service: Movement Analysis
• 4.3. Preclinical CRO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 4.4. Bioanalysis and DMPK studies
  • 4.4.1. Bioanalysis and DMPK studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. In vitro ADME
    • 4.4.2.1. In vitro ADME Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. In vivo PK
    • 4.4.3.1. In vivo PK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Toxicology Testing
  • 4.5.1. Toxicology Testing Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. GLP
    • 4.5.2.1. GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Non-GLP
    • 4.5.3.1. Non-GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Compound Management
  • 4.6.1. Compound Management Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Process R&D
    • 4.6.2.1. Process R&D Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Custom Synthesis
    • 4.6.3.1. Custom Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Others
    • 4.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Chemistry
  • 4.7.1. Chemistry Market Estimates & Forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. Medicinal Chemistry
    • 4.7.2.1. Medicinal Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7.3. Computational Chemistry
    • 4.7.3.1. Computational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8.1. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Preclinical CRO Market: Development Stage Estimates & Trend Analysis

• 5.1. Preclinical CRO Market, By Development Stage: Segment Dashboard
• 5.2. Preclinical CRO Market, By Development Stage: Movement Analysis
• 5.3. Preclinical CRO Market Estimates & Forecasts, By Development Stage, 2021 - 2033 (USD Million)
• 5.4. Target Discovery
  • 5.4.1. Target Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Finished Preclinical Optimization, Efficacy & PK/PD
  • 5.5.1. Finished Preclinical Optimization, Efficacy & PK/PD Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. IND-Enabling Safety (GLP)
  • 5.6.1. IND-Enabling Safety (GLP) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Bioanalysis & Analytics
  • 5.7.1. Bioanalysis & Analytics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Preclinical CRO Market: Indication Estimates & Trend Analysis

• 6.1. Preclinical CRO Market, By Indication: Segment Dashboard
• 6.2. Preclinical CRO Market, By Indication: Movement Analysis
• 6.3. Preclinical CRO Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. CNS
  • 6.5.1. CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Infectious Diseases
  • 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Cardiovascular Diseases
  • 6.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Metabolic Disorders
  • 6.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Rare Diseases
  • 6.9.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Preclinical CRO Market: Model Estimates & Trend Analysis

• 7.1. Preclinical CRO Market, By Model: Segment Dashboard
• 7.2. Preclinical CRO Market, By Model: Movement Analysis
• 7.3. Preclinical CRO Market Estimates & Forecasts, By Model, 2021 - 2033 (USD Million)
• 7.4. In Vitro
  • 7.4.1. In vitro Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. In Vivo
  • 7.5.1. In Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Ex Vivo
  • 7.6.1. Ex Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Preclinical CRO Market: End Use Estimates & Trend Analysis

• 8.1. Preclinical CRO Market, By End Use: Segment Dashboard
• 8.2. Preclinical CRO Market, By End Use: Movement Analysis
• 8.3. Preclinical CRO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 8.4. Pharmaceutical and Biopharmaceutical Companies
  • 8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Medical Device Companies
  • 8.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Academic and Research Institutions
  • 8.6.1. Academic and Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Others
  • 8.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Preclinical CRO Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market Share Analysis, 2025 & 2033
• 9.3. North America
  • 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. U.S
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Competitive Scenario
    • 9.4.8.3. Regulatory Framework
    • 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Competitive Scenario
    • 9.4.9.3. Regulatory Framework
    • 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.4. Saudi Arabia
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.6. Qatar
    • 9.7.6.1. Key Country Dynamics
    • 9.7.6.2. Competitive Scenario
    • 9.7.6.3. Regulatory Framework
    • 9.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.7. Oman
    • 9.7.7.1. Key Country Dynamics
    • 9.7.7.2. Competitive Scenario
    • 9.7.7.3. Regulatory Framework
    • 9.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Key Participant Categorization
  • 10.1.1. Market Leaders
  • 10.1.2. Emerging Players
• 10.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 10.3. Company Profiles
  • 10.3.1. Eurofins Scientific
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Performance
    • 10.3.1.3. Service Benchmarking
    • 10.3.1.4. Strategic Initiatives
  • 10.3.2. ICON plc
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Service Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. WuXi AppTec
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Service Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. Medpace Holdings, Inc.
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Service Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Charles River Laboratories
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Service Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. PPD (Thermo Fisher Scientific, Inc.)
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Service Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. SGS SA (SGS Societe Generale de Surveillance SA.)
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Service Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Intertek Group plc (IGP)
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Service Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Labcorp
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Service Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Crown Bioscience
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Service Benchmarking
    • 10.3.10.4. Strategic Initiatives
  • 10.3.11. Scantox
    • 10.3.11.1. Company Overview
    • 10.3.11.2. Financial Performance
    • 10.3.11.3. Service Benchmarking
    • 10.3.11.4. Strategic Initiatives